AstraZeneca to Acquire EsoBiotec

AstraZeneca Acquires Fusion Pharmaceuticals

March 19, 2024

Biotechnology

AstraZeneca has entered into a definitive agreement to acquire Fusion Pharmaceuticals Inc., a clinical-stage company developing next-generation actinium-based radioconjugates, for $21.00 per share in cash plus a non-transferable contingent value right that could bring the total to approximately $2.4 billion. The acquisition adds Fusion's pipeline (including FPI-2265 for mCRPC), R&D and manufacturing capabilities in radioconjugates and strengthens AstraZeneca's oncology portfolio and presence in Canada.

AstraZeneca (Alexion) Acquires Amolyt Pharma for Up to $1.05 Billion

March 14, 2024

Biotechnology

Amolyt Pharma, a clinical-stage biotech focused on rare endocrine diseases, entered into a definitive agreement to be acquired by AstraZeneca’s Rare Disease business (Alexion) for $800 million upfront plus up to $250 million in regulatory milestone contingent payments. The total deal value is up to $1.05 billion and is expected to close by the end of Q3 2024, subject to customary closing conditions and regulatory clearances.

AstraZeneca to Acquire Gracell Biotechnologies (FasTCAR CAR-T) for Up to $1.2 Billion

December 27, 2023

Healthcare Services

AstraZeneca entered into a definitive agreement to acquire Gracell Biotechnologies, a global clinical-stage biopharmaceutical company focused on autologous cell therapies for cancer and autoimmune diseases. The deal is expected to close in the first quarter of 2024 and includes Gracell’s FasTCAR-enabled dual-targeting CAR-T therapy GC012F, with an upfront value of about $1.0 billion and total transaction value of up to about $1.2 billion including a contingent value right tied to a regulatory milestone.

AstraZeneca Acquires Icosavax

December 12, 2023

Biotechnology

AstraZeneca has entered into a definitive agreement to acquire Icosavax, a Seattle-based clinical-stage biopharmaceutical company, in a cash tender offer valuing the deal at approximately $0.8bn upfront and up to $1.1bn including contingent payments. The acquisition brings Icosavax's virus‑like particle (VLP) platform and Phase III‑ready combination RSV/hMPV vaccine candidate IVX‑A12 into AstraZeneca's Vaccines & Immune Therapies late‑stage pipeline to strengthen respiratory vaccine capabilities for older adults and vulnerable populations.

AstraZeneca Acquires Neogene Therapeutics

November 29, 2022

Biotechnology

AstraZeneca has agreed to acquire Neogene Therapeutics, a clinical-stage biotechnology company focused on next-generation T-cell receptor (TCR) therapies, for up to $320 million. The acquisition strengthens AstraZeneca's oncology cell therapy capabilities by adding Neogene's discovery, development and manufacturing expertise for TCR-Ts targeting solid tumours.

Astellas Pharma Acquires Xyphos Biosciences

December 26, 2019

Biotechnology

Astellas Pharma has acquired Xyphos Biosciences, gaining Xyphos' ACCEL convertible-CAR technology platform and immuno-oncology talent. The deal included $120 million paid at closing and potential milestone payments bringing the total transaction value to up to $665 million.